Jason S. Lewis: Publications

Share

Viola-Villegas NT, Carlin SD, Ackerstaff E, Sevak KK, Divilov V, Serganova I, Kruchevsky N, Anderson M, Blasberg RG, Andreev OA, Engelman DM, Koutcher JA, Reshetnyak YK, Lewis JS. Understanding the Pharmacological Properties of a Metabolic PET Tracer in Prostate Cancer, Proceedings of the National Academy of Sciences (PNAS), 111, 7254-7259, 2014.

Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko SK, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS*, Thompson CB*. Glutamine Based PET Imaging Facilitates Enhanced Metabolic Evaluation of Gliomas In Vivo. Science Translational Medicine, 7, 274ra17, 2015.

Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS*, Sawyers CL*. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Research, 75, 4688-4696 2015.

Houghton JL, Zeglis BM, Abdel-Atti D, Aggeler R, Sawada R, Agnew BJ, Scholz WW, Lewis JS. Site-Specifically Labeled CA19.9-Targeted Immunoconjugates for the PET, NIRF, and Multimodal PET/NIRF Imaging of Pancreatic Cancer. Proceedings of the National Academy of Sciences (PNAS), 112, 15850-15855, 2015.

Houghton JL, Membreno R, Abdel-Atti D, Cunanan KM, Carlin S, Scholz WW, Zanzonico PB, Lewis JS, Zeglis BM. Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry. Molecular Cancer Therapeutics, 16, 124-133, 2017.

Sharma SK, Pourat J, Abdel-Atti D, Carlin SD, Piersigilli A, Bankovich AJ, Gardner EE, Hamdy O, Isse K, Bheddah S, Sandoval J, Cunanan KM, Johansen EB, Allaj V, Sisodiya V, Liu D, Zeglis BM, Rudin CM, Dylla SJ, Poirier JT, LewisJS. Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Research, 77, 3942-3970, 2017.

Meyer JP, Kozlowski P, Jackson J, Cunanan KM, Adumeau P, Dilling TR, Zeglis BM, Lewis JS. Exploring Structural Parameters for Pretargeting Radioligand Optimization. Journal of Medicinal Chemistry, 60, 8201-8217, 2017.

Sharma SK, Pourat J, Abdel-Atti D, Carlin SD, Piersigilli A, Bankovich AJ, Gardner EE, Hamdy O, Isse K, Bheddah S, Sandoval J, Cunanan KM, Johansen EB, Allaj V, Sisodiya V, Liu D, Zeglis BM, Rudin CM, Dylla SJ, Poirier JT, LewisJS. Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Research, 77, 3942-3970, 2017.

Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi E, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico P, Gerecitano JF, Kelsen DP, Weber WA, Lyashchenko SK, Kung HF, Lewis JS. First-in-human Trial of [18F](2S,4R)-4-Fluoroglutamine: An Investigational PET Biomarker of Tumor Glutamine Flux and Metabolism. Radiology, 287, 667-675, 2018.

Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, Dilling TR, Abdel-Atti D, Zeglis BM, Poirier JT, Lewis JS. Fc-mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. Cancer Research, 78, 1820-1832, 2018.

Pereira PMR, Sharma SK, Carter LM, Edwards KJ, Pourat J, Ragupathi A, Janjigian YY, Durack JC, Lewis JS. Caveolin-1 Mediates Cellular Distribution of HER2 and Affects Trastuzumab Binding and Therapeutic Efficacy. Nature Communications, 9, 5137, 2018.

Henry KE, Dacek MM, Dilling TR, Caen JD, Fox IL, Evans MJ, Lewis JS. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clinical Cancer Research, 25, 166-176, 2019.

Poty S, Carter LM, Mandleywala K, Membreno R, Abdel-Atti D, Ragupathi A, Scholz WS, Zeglis BM. Lewis JS. Leveraging bioorthogonal click chemistry to improve 225Ac-radioimmunotherapy of pancreatic ductal adenocarcinoma. Clinical Cancer Research, 25, 868-880, 2019.

Nagle VL, Henry KE, Hertz CAJ, Graham MS, Campos C, Parada LF, Pandit-Taskar N, Schietinger A, Mellinghoff IK, Lewis JS. Imaging Tumor-Infiltrating Lymphocytes in Glioblastoma with [64Cu]Cu-NOTA-anti-CD8-PET. Clinical Cancer Research, 27, 1958-1966, 2021.